The economic value of a visceral leishmaniasis vaccine in Bihar state, India.

TitleThe economic value of a visceral leishmaniasis vaccine in Bihar state, India.
Publication TypeJournal Article
Year of Publication2012
AuthorsLee BY, Bacon KM, Shah M, Kitchen SBeth, Connor DL, Slayton RB
JournalAm J Trop Med Hyg
Volume86
Issue3
Pagination417-25
Date Published2012 Mar
ISSN1476-1645
KeywordsCost of Illness, Cost-Benefit Analysis, Endemic Diseases, Health Care Costs, Humans, India, Leishmania, Leishmaniasis Vaccines, Leishmaniasis, Visceral
Abstract

Visceral leishmaniasis (VL) is responsible for substantial morbidity and mortality and current available treatments have many limitations. The ability of VL infection to generate life-long immunity offers promise for the development of a VL vaccine. A VL vaccine candidate has recently completed phase I clinical trials. We constructed a computer simulation model to determine the potential economic value of a VL vaccine in the endemic region of Bihar state, India. Results found a potential vaccine to be cost-effective (and in many cases economically dominant, i.e., saving costs and providing health benefits) throughout a wide range of vaccination costs and vaccine efficacies, and VL risks. Overall, our study strongly supports the continued development of a VL vaccine.

DOI10.4269/ajtmh.2012.10-0415
Alternate JournalAm. J. Trop. Med. Hyg.
PubMed ID22403311
PubMed Central IDPMC3284356
Grant List5U54GM088491-02 / GM / NIGMS NIH HHS / United States
U54 GM088491 / GM / NIGMS NIH HHS / United States
Publication Categories: